BioDelivery Sciences Announces Further Significant Expanded Preferred Coverage For BELBUCA®
November 01, 2018 16:10 ET
|
BioDelivery Sciences International, Inc.
More than 100 million Covered Lives Now Have Preferred Access to BELBUCA RALEIGH, N.C., Nov. 01, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly...
BioDelivery Sciences to Report Third Quarter 2018 Financial Results on November 8, 2018
October 23, 2018 08:00 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Oct. 23, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients...
SPR Therapeutics Awarded $10M From U.S. Department of Defense
October 02, 2018 10:30 ET
|
SPR Therapeutics, Inc.
CLEVELAND, Oct. 02, 2018 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, has been awarded two new grants and one new contract from the U.S....
BioDelivery Sciences to Present at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 2018 Healthcare Conference
September 25, 2018 08:00 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Sept. 25, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences to Host Institutional Investor and Analyst Day on Friday, October 5, 2018
September 13, 2018 07:30 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Sept. 13, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
August 21, 2018 08:00 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Aug. 21, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc., (NASDAQ:BDSI), a leading commercial specialty pharmaceutical company dedicated to patients living with...
FDA Clears SPR Therapeutics’ Non-opioid SPRINT endura and extensa Peripheral Nerve Stimulation Systems for Pain Management
August 16, 2018 08:30 ET
|
SPR Therapeutics, Inc.
SPRINT® is the First and Only Dual Lead Capable PNS Platform Company also provides first look at 12-month durability outcomes following 60-day SPRINT therapy CLEVELAND, Aug. 16, 2018 (GLOBE...
BioDelivery Sciences Secures Significant Expanded Preferred Coverage for BELBUCA®
August 15, 2018 09:26 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Aug. 15, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a leading commercial specialty pharmaceutical company dedicated to patients living with...
BioDelivery Sciences Reports Strong Second Quarter 2018 Financial Results
August 09, 2018 16:05 ET
|
BioDelivery Sciences International, Inc.
BELBUCA® Continues Its Accelerated Record Prescription Growth of 80% YOY and 31% Versus the Prior Quarter Company Provides Overview of New Plan to Capitalize on Long Term Net Revenue Potential of...
BioDelivery Sciences Appoints Thomas Smith, MD as Chief Medical Officer Further Expanding Company’s Expertise in Field of Pain Management
July 30, 2018 07:55 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., July 30, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a leading commercial based specialty pharmaceutical company focused on patients living with...